The Role of Membrane-Associated E3 Ubiquitin Ligases in Cancer.

Chen, Xuankun; Jiang, Li; Zhou, Zhesheng; Yang, Bo; He, Qiaojun; Zhu, Chengliang; Cao, Ji

Chen, Xuankun; Jiang, Li; Zhou, Zhesheng; Yang, Bo; He, Qiaojun; Zhu, Chengliang; Cao, Ji.

Afiliação

Chen X; Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Institute of Pharmacology and Toxicology, Zhejiang University, Hangzhou, China.
Jiang L; Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Institute of Pharmacology and Toxicology, Zhejiang University, Hangzhou, China.
Zhou Z; Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Institute of Pharmacology and Toxicology, Zhejiang University, Hangzhou, China.
Yang B; Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Institute of Pharmacology and Toxicology, Zhejiang University, Hangzhou, China.
He Q; The Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University, Hangzhou, China.
Zhu C; Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Institute of Pharmacology and Toxicology, Zhejiang University, Hangzhou, China.
Cao J; Center for Drug Safety Evaluation and Research of Zhejiang University, Zhejiang University, Hangzhou, China.

Front Pharmacol ; 13: 928794, 2022.

Article em En | MEDLINE | ID: mdl-35847032

Palavras-chave

E3 ligases; PROTAC (proteolysis-targeting chimeric molecule); cancer; cell membrane system; drug targets

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: Front Pharmacol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google